Tygacil — Competitive Intelligence Brief

Tygacil (Tigecycline) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tetracycline. Area: Metabolic.

marketed Tetracycline Bacterial protein synthesis Metabolic Small molecule

Target snapshot

Tygacil (Tigecycline) — Pfizer. Tigecycline is a tetracycline class antibacterial agent.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tygacil TARGET	Tigecycline	Pfizer	marketed	Tetracycline	Bacterial protein synthesis	2005-01-01
Clindamycin/benzoyl peroxide plus Adapalene	Clindamycin/benzoyl peroxide plus Adapalene	Allergan	marketed	Topical acne combination therapy	Bacterial protein synthesis (clindamycin); reactive oxygen species generation (benzoyl peroxide); retinoic acid receptors (adapalene)
PPI, amoxicillin, metronidazole and clarithromycin	PPI, amoxicillin, metronidazole and clarithromycin	Infante, Javier Molina, M.D.	marketed	Antibiotic combination therapy with acid suppression	Helicobacter pylori (bacterial pathogen); PPI targets H+/K+-ATPase; amoxicillin targets bacterial cell wall; metronidazole and clarithromycin target bacterial protein synthesis
ABPO Forte Gel	ABPO Forte Gel	Galderma R&D	marketed	Topical antimicrobial and keratolytic agent	Bacterial protein synthesis inhibition; mitochondrial oxidative stress in bacteria
Loteprednol and tobramycin	Loteprednol and tobramycin	Bausch & Lomb Incorporated	marketed	Corticosteroid/aminoglycoside combination	Inflammatory mediators and bacterial protein synthesis
Duac Gel	Duac Gel	Stiefel, a GSK Company	marketed	Topical antibiotic combination	Propionibacterium acnes (bacterial target); benzoyl peroxide acts via oxidative mechanism; clindamycin inhibits bacterial protein synthesis
Budesonide + Salmeterol + Azithromycin	Budesonide + Salmeterol + Azithromycin	National Heart, Lung, and Blood Institute (NHLBI)	marketed	Combination therapy: inhaled corticosteroid + long-acting beta-2 agonist + macrolide antibiotic	Glucocorticoid receptor (budesonide); beta-2 adrenergic receptor (salmeterol); bacterial protein synthesis inhibition (azithromycin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2028-10-24 — Tygacil · 8975242 · US
• 2029-02-05 — Tygacil · 7879828 · US
• 2030-10-08 — Tygacil · 8372995 · US
• 2033-04-07 — Tygacil · 9855335 · US

Sponsor landscape (Tetracycline class)

1. · 1 drug in this class
2. Pfizer · 1 drug in this class